Author

J. Sakal

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Assay:clinical cohort / trial· 1 Approach:deep learning· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Organism:non-human primate· 1

Frequent Co-Authors

H. J. Borish· 2 shared J. L. Flynn· 2 shared P. L. Lin· 2 shared P. Maiello· 2 shared A. A. Smith· 1 shared A. G. White· 1 shared A. W. Simonson· 1 shared C. A. Scanga· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

H. J. Borish

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A "suicide" BCG strain provides enhanced immunogenicity and robust protection against Mycobacterium tuberculosis in macaques

A. A. Smith, H. Su, J. Wallach, Y. Liu, P. Maiello, H. J. Borish, C. Winchell, A. W. Simonson, P. L. Lin, M. Rodgers, D. J. Filmore, J. Sakal, K. Lin, V. Vinette, D. Schnappinger, , J. L. Flynn

This study develops a 'suicide' BCG strain that is safely eliminated in immunocompromised hosts but induces stronger immune responses and better protection against Mtb in macaques.

bioRxiv · Nov 22, 2023 · PreprintImmunology

Optimizing tuberculosis treatment efficacy: comparing the standard regimen with Moxifloxacin-containing regimens

M. Budak, J. M. Cicchese, P. Maiello, H. J. Borish, A. G. White, H. B. Chishti, J. Tomko, L. J. Frye, D. Fillmore, K. Kracinovsky, J. Sakal, C. A. Scanga, P. L. Lin, V. Dartois, J. J. Linderman, , D. E. Kirschner

This study compares standard TB treatment with moxifloxacin-containing regimens using computational models and experimental validation to identify more effective and patient-friendly treatment options.

bioRxiv · Dec 18, 2022Pharmacology & Toxicology